Delivery Order SPE2DB25D9365-SPE2DB25FUJSD

DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,561.15 by the Defense Logistics Agency (DLA) on September 15, 2025. The delivery order, which has an ultimate completion date of October 6, 2025, is for the supply of Xolair 300 mg/2 ml auto-injector syringes to support Department of Defense healthcare operations. This award carries no set-aside designation, allowing the vendor to compete on an unrestricted basis despite its woman-owned small business status. The contract was issued under the DLA's larger Indefinite Delivery Contract (IDC) vehicle valued at $499,999,999 through the SPE2DB program, which enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for military health facilities nationwide.

DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, holding a significant single-award IDC with the DLA that authorizes delivery orders for branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables across multiple product categories. The company's contract portfolio with DLA demonstrates consistent success in federal procurement, with past awards covering diverse pharmaceutical products including specialty auto-injectors, oncology treatments, vaccines, and contraceptive devices. This delivery order for Xolair, a biologic immunosuppressant used in the treatment of moderate-to-severe allergic asthma and chronic idiopathic urticaria, reflects the vendor's ongoing role in supplying specialty medications to Department of Defense medical facilities.